Marc Bonaca

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Antithrombotics in acute coronary syndromes: updates from the past year
    Marc Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 12:84-99. 2010
  2. doi request reprint Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    JACC Cardiovasc Interv 9:2157-2164. 2016
  3. doi request reprint Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
    Marc P Bonaca
    From TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA M P B, D L B, E G, D A M, E B, M S Tokai University School of Medicine Institute of Medical Science, Isehara, Japan S G FACT, DHU FIRE INSERM Unité 1148, Assistance Publique Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK P G S University of Sheffield, United Kingdom R F S Division of Cardiology, Newark Beth Israel Medical Center, Rutgers New Jersey Medical School, Newark M C Brigham and Women s Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA L M CWZ Hospital, Nijmegen, The Netherlands T O O Cardiology Research and Production complex MH RF, Moscow, Russia M R Internal Cardiology Department, University Hospital and Medical Faculty, Brno, Czech Republic J S Seoul St Mary s Hospital, College of Medicine, The Catholic University of Korea K B S Heart Institute, Intervention Center, People Hospital of Peking University, China D H Life Fourways Hospital
    Circulation 134:861-71. 2016
  4. doi request reprint Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital Heart and Vascular Center, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 67:2719-28. 2016
  5. doi request reprint Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Heart and Vascular Center, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 37:1133-42. 2016
  6. doi request reprint Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarct
    Marc P Bonaca
    From TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA M P B, J A G, B M S, S A H, E B, D A M Dartmouth Hitchcock Heart and Vascular Center, Geisel School of Medicine at Dartmouth, Lebanon, NH M A C and Wiener Cardiovascular Institute and Marie Jose and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY J O
    Circulation 133:997-1005. 2016
  7. doi request reprint Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36
    Marc P Bonaca
    Department of Medicine, Brigham and Women s Hospital, Boston, USA
    Eur Heart J Acute Cardiovasc Care 4:431-40. 2015
  8. doi request reprint Pharmacological treatment and current management of peripheral artery disease
    Marc P Bonaca
    From the Vascular Medicine Section, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA
    Circ Res 116:1579-98. 2015
  9. doi request reprint New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2318-26. 2014
  10. doi request reprint Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2309-17. 2014

Detail Information

Publications23

  1. doi request reprint Antithrombotics in acute coronary syndromes: updates from the past year
    Marc Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 12:84-99. 2010
    ..Incremental updates to guideline recommendations from established expert groups will be important in providing guidance...
  2. doi request reprint Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    JACC Cardiovasc Interv 9:2157-2164. 2016
    ....
  3. doi request reprint Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
    Marc P Bonaca
    From TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA M P B, D L B, E G, D A M, E B, M S Tokai University School of Medicine Institute of Medical Science, Isehara, Japan S G FACT, DHU FIRE INSERM Unité 1148, Assistance Publique Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK P G S University of Sheffield, United Kingdom R F S Division of Cardiology, Newark Beth Israel Medical Center, Rutgers New Jersey Medical School, Newark M C Brigham and Women s Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA L M CWZ Hospital, Nijmegen, The Netherlands T O O Cardiology Research and Production complex MH RF, Moscow, Russia M R Internal Cardiology Department, University Hospital and Medical Faculty, Brno, Czech Republic J S Seoul St Mary s Hospital, College of Medicine, The Catholic University of Korea K B S Heart Institute, Intervention Center, People Hospital of Peking University, China D H Life Fourways Hospital
    Circulation 134:861-71. 2016
    ..We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population...
  4. doi request reprint Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital Heart and Vascular Center, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 67:2719-28. 2016
    ..Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI)...
  5. doi request reprint Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Heart and Vascular Center, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 37:1133-42. 2016
    ..We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy...
  6. doi request reprint Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarct
    Marc P Bonaca
    From TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA M P B, J A G, B M S, S A H, E B, D A M Dartmouth Hitchcock Heart and Vascular Center, Geisel School of Medicine at Dartmouth, Lebanon, NH M A C and Wiener Cardiovascular Institute and Marie Jose and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY J O
    Circulation 133:997-1005. 2016
    ..We investigated the causes, sequelae, and predictors of ALI in a contemporary population with symptomatic PAD and whether protease-activated receptor 1 antagonism with vorapaxar reduced ALI overall and by type...
  7. doi request reprint Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36
    Marc P Bonaca
    Department of Medicine, Brigham and Women s Hospital, Boston, USA
    Eur Heart J Acute Cardiovasc Care 4:431-40. 2015
    ..We evaluated the prognostic implications of low-level increases in cardiac troponin I (cTnI) using an investigational single-molecule high-sensitivity assay in patients with acute coronary syndrome (ACS)...
  8. doi request reprint Pharmacological treatment and current management of peripheral artery disease
    Marc P Bonaca
    From the Vascular Medicine Section, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA
    Circ Res 116:1579-98. 2015
    ..Ongoing trials of novel therapies in patients with PAD will further inform pharmacological strategies to reduce both systemic cardiovascular risk and limb-related morbidity. ..
  9. doi request reprint New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2318-26. 2014
    ....
  10. doi request reprint Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2309-17. 2014
    ..Vorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease...
  11. doi request reprint Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Cardiol Rep 16:536. 2014
    ..The optimal care of patients with acute aortic syndrome requires the cooperation of members of an experienced multidisciplinary team both in the acute and chronic setting. ..
  12. doi request reprint Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 127:1522-9, 1529e1-6. 2013
    ..Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization...
  13. doi request reprint Management of asymptomatic carotid artery stenosis
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 15:252-63. 2013
    ..The most important aspect of the management of asymptomatic carotid artery stenosis is reducing the overall cardiovascular risk of the patient...
  14. doi request reprint Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012
    ..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)...
  15. doi request reprint American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 125:577-83. 2012
    ..The prognostic implications of MI defined in the current era have not been well described...
  16. ncbi request reprint Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  17. doi request reprint Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 31:203-10. 2011
    ....
  18. doi request reprint Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I
    Marc Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:2118-24. 2010
    ..The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS)...
  19. doi request reprint SCH 530348: a novel oral thrombin receptor antagonist
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Future Cardiol 5:435-42. 2009
    ..Two large Phase III clinical outcome trials are currently underway to evaluate the safety and efficacy of SCH 530348 for the management of acute coronary syndromes and the secondary prevention of atherothrombotic events...
  20. doi request reprint Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  21. doi request reprint Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  22. doi request reprint Antithrombotics in acute coronary syndromes
    Marc P Bonaca
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:969-84. 2009
    ..In addition to reviewing existing agents, we take a look forward at the most promising new antithrombotics currently in late-stage clinical development and their potential role in the context of ACS management...
  23. doi request reprint Defining a role for novel biomarkers in acute coronary syndromes
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 54:1424-31. 2008
    ..Active investigation has brought forward an increasingly large number of novel candidate markers; however, few of these markers have yet to be incorporated into routine clinical use...